Literature DB >> 19289271

Expected reduction of colorectal cancer incidence within 8 years after introduction of the German screening colonoscopy programme: estimates based on 1,875,708 screening colonoscopies.

Hermann Brenner1, Michael Hoffmeister, Gerhard Brenner, Lutz Altenhofen, Ulrike Haug.   

Abstract

In late 2002, colonoscopy was introduced as a primary screening tool for colorectal cancer (CRC) in Germany. We aimed to estimate the expected reduction in case numbers and incidence of CRC between 2003 and 2010 by detection and removal of advanced adenomas. Data from 1,875,708 women and men included in the national screening colonoscopy database were combined with estimates of transition rates of advanced adenomas and with national population projections. Despite relatively low screening participation, incident CRC cases are expected to be reduced by more than 15,000 between 2003 and 2010. The impact is expected to be largest in age groups 55-59, 60-64 and 65-69 in whom total case numbers in 2010 are expected to be reduced by 13%, 19% and 14% among women, and by 11%, 15% and 12%, respectively, among men. Our results forecast a major rapid reduction of the CRC burden in Germany by screening colonoscopy.

Entities:  

Mesh:

Year:  2009        PMID: 19289271     DOI: 10.1016/j.ejca.2009.02.017

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  14 in total

1.  Colorectal cancer incidence trends in the United States and United kingdom: evidence of right- to left-sided biological gradients with implications for screening.

Authors:  Rafael Meza; Jihyoun Jeon; Andrew G Renehan; E Georg Luebeck
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  Colonoscopy screening in Germany--a success story?

Authors:  Stefanie J Klug
Journal:  Dtsch Arztebl Int       Date:  2010-10-29       Impact factor: 5.594

3.  Detection of relevant colonic neoplasms with PET/CT: promising accuracy with minimal CT dose and a standardised PET cut-off.

Authors:  Wolfgang Luboldt; Teresa Volker; Bärbel Wiedemann; Klaus Zöphel; Ursula Wehrmann; Arne Koch; Todd Toussaint; Nasreddin Abolmaali; Markus Middendorp; Daniela Aust; Jörg Kotzerke; Frank Grünwald; Thomas J Vogl; Hans-Joachim Luboldt
Journal:  Eur Radiol       Date:  2010-05-26       Impact factor: 5.315

4.  Comparison of diagnostic accuracy and interpretation times for a standard and an advanced 3D visualisation technique in CT colonography.

Authors:  Thomas Mang; Frank T Kolligs; Claus Schaefer; Maxmilian F Reiser; Anno Graser
Journal:  Eur Radiol       Date:  2010-10-03       Impact factor: 5.315

5.  [Endoscopy in otorhinolaryngology].

Authors:  N Stasche
Journal:  HNO       Date:  2009-12       Impact factor: 1.284

6.  Eight years of colonoscopic bowel cancer screening in Germany: Initial findings and projections. Complete and comprehensible data are required.

Authors:  Ingrid Mühlhauser
Journal:  Dtsch Arztebl Int       Date:  2011-03-11       Impact factor: 5.594

7.  Why so late?!--delay in treatment of colorectal cancer is socially determined.

Authors:  Mike Ralf Langenbach; Stefan Sauerland; Karl-Wilhelm Kröbel; Hubert Zirngibl
Journal:  Langenbecks Arch Surg       Date:  2010-06-27       Impact factor: 3.445

8.  Eight years of colonoscopic bowel cancer screening in Germany: initial findings and projections.

Authors:  Hermann Brenner; Lutz Altenhofen; Michael Hoffmeister
Journal:  Dtsch Arztebl Int       Date:  2010-10-29       Impact factor: 5.594

Review 9.  Colorectal cancer screening: 20 years of development and recent progress.

Authors:  Miroslav Zavoral; Stepan Suchanek; Ondrej Majek; Premysl Fric; Petra Minarikova; Marek Minarik; Bohumil Seifert; Ladislav Dusek
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

10.  Survival from colorectal cancer in Germany in the early 21st century.

Authors:  O Majek; A Gondos; L Jansen; K Emrich; B Holleczek; A Katalinic; A Nennecke; A Eberle; H Brenner
Journal:  Br J Cancer       Date:  2012-05-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.